9995.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (28 6月 2024 @ 17:08):
Our systems believe the stock currently is undervalued by 0.04% compare to its pairs and should correct upwards.

Stats
本日の出来高	1.35M
平均出来高	1.51M
時価総額	22.78B
EPS	HKD-0.650 ( Q1 \| 2024-03-31 )
次の収益日	( HKD0 ) 2024-08-20
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-8.14 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0.0290 (0.12%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

相関 (AI algo v.1.1b): Undervalued: 0.04% HKD24.51 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: -0.12 (neutral)

短: 0.71 (moderate)

Signal:(46.118) Neutral

REMEGEN-B 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

REMEGEN-B 相関 - 通貨/商品

0.10
( neutral )

0.23
( neutral )

0.00
( neutral )

0.40
( neutral )

-0.24
( neutral )

-0.07
( neutral )

REMEGEN-B 財務諸表

Annual	2023
収益:	HKD1.08B
総利益:	HKD822.99M (76.48 %)
EPS:	HKD-2.80

FY	2023
収益:	HKD1.08B
総利益:	HKD822.99M (76.48 %)
EPS:	HKD-2.80

FY	2022
収益:	HKD767.78M
総利益:	HKD497.84M (64.84 %)
EPS:	HKD-1.880

FY	2021
収益:	HKD1.42B
総利益:	HKD1.36B (95.28 %)
EPS:	HKD0.680

Financial Reports:

No articles found.

REMEGEN-B Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

REMEGEN-B

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.